Medullary thyroid carcinoma: Management of lymph node metastases

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 5, 2010, Pages 549-556

  Moley, Jeffrey F ^a,b  

^a USA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Lymph node metastasis; Malignancy; Medullary thyroid cancer; Multiple endocrine neoplasia; Neck dissection; Thyroid gland; Thyroidectomy

Indexed keywords

CALCITONIN; CALCIUM; CARCINOEMBRYONIC ANTIGEN; LABETUZUMAB; PENTAGASTRIN; PROTEIN RET; RADIOACTIVE IODINE; VANDETANIB;

ADVANCED CANCER; ARTICLE; ASPIRATION BIOPSY; AUTOTRANSPLANTATION; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CERVICAL LYMPH NODE; CLINICAL TRIAL; CODON; EXTERNAL BEAM RADIOTHERAPY; FAMILIAL CANCER; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HUMAN; INTRAOPERATIVE PERIOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MOLECULARLY TARGETED THERAPY; NECK DISSECTION; NEUROFIBROMATOSIS; PARATHYROIDECTOMY; PHEOCHROMOCYTOMA; POSTOPERATIVE PERIOD; PRIMARY TUMOR; PROTEIN BLOOD LEVEL; PROVOCATION TEST; RADIATION DOSE; RECURRENT CANCER; RECURRENT LARYNGEAL NERVE PALSY; REOPERATION; SENSITIVITY AND SPECIFICITY; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROID SURGERY; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 77952970595     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0042     Document Type: Article

References (48)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 1998;83:2638-2648.
2. Bergholm U, Adami HO, Bergstrom R, et al. Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group. Ann Med Interne (Paris) 1990;141:20-25.
3. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-1148.
4. Dralle H. Lymph node dissection and medullary thyroid carcinoma. Br J Surg 2002;89:1073-1075.
5. Moley JF, Fialkowski EA. Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 2007;31:946-956.
6. Tisell LE, Dilley WG, Wells SA. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Adv Anat Embryol Cell Biol 1996;132:1-56.
7. Gimm O, Dralle H. Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 1997;122:1124-1130; discussion 30-31.
8. Moley JF, Wells SA, Dilley WG, Tisell LE. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993;114:1090-1095; discussion 1095-1096.
9. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077-6084.
10. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999;229:880-887; discussion 887-888.
11. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002;26:22-28.
12. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 2007;31:1960-1965.
13. Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996;77:1556-1565.
14. Rendl G, Manzl M, Hitzl W, et al. Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2008;69:497-505.
15. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
16. Kloos RT, Eng C, Evans DB, et al. Medullary thryoid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
17. Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Thyroid 1994;4:93-98.
18. Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999;230:697-707.
19. Carry SE, Cooper DS, Doherty G, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009;19:1153-1158.
20. Musholt TJ, Musholt PB, Dehdashti F, Moley JF. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 1997;122:1049-1060; discussion 60-61.
21. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134:946-954; discussion 954-955.
22. Machens A, Holzhausen HJ, Dralle H. Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg 2004;139:43-45.
23. Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 2008;95:586-591.
24. Solorzano CC, Evans DB. Same-day ultrasound guidance in reoperations for locally recurrent papillary thyroid cancer. Surgery 2007;142:973-975. (Pubitemid 350186323)
25. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-1113. (Pubitemid 41317433)
26. Olson JA, DeBenedetti MK, Baumann DS, Wells SA. Parathyroid autotransplantation during diyroidectomy. Results of long-term follow-up. Ann Surg 1996;223:472-478; discussion 478-480.
27. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Chirurg 1994;65:48-49.
28. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525. (Pubitemid 37255037)
29. Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic diyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-247; discussion 247-250.
30. Frilling A, Dralle H, Eng C, et al. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 1995;118:1099-1103; discussion 1103-1104.
31. Lips CJ, Landsvater RM, Hoppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:870-871.
32. Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006;24:4642-4660.
33. Jackson CE, Norum RA, Talpos GB, et al. Clinical value of calcitonin and carcinoembryonic antigen doubling times in medullary thyroid carcinoma. Henry Ford Hosp Med J 1987;35:133-138.
34. Laure Giraudet A, Al Ghulzan A, Auperin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008;158:239-246. (Pubitemid 351298542)
35. van Heerden JA, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Arch Intern Med 1990;150:2125-2128. (Pubitemid 20369771)
36. Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 2008;32:754-765.
37. Clark JR, Fridman TR, Odell MJ, et al. Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 2005;115:1445-1450. (Pubitemid 41105855)
38. Buhr HJ, Kallinowski F, Raue F, et al. Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results. Cancer 1993;72:3685-3693. (Pubitemid 24000605)
39. Ellenhorn JD, Shah JP, Brennan MF. Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 1993;114:1083-1089.
40. Tisell LE, Jansson S. Recent results of reoperative surgery in medullary carcinoma of the thyroid. Surg Gynecol Obstet 1988;166:567-579.
41. Tung WS, Vesely TM, Moley JF. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995;118:1031-1035.
42. Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. J Endocrinol 1986;108:17-23. (Pubitemid 16145521)
43. Moley JF, Lairmore TC, Doherty GM, et al. Preservation of the recurrent laryngeal nerves in thyroid and parathyroid reoperations. Surgery 1999;126:673-677; discussion 677-679.
44. Faik Erdogan M, Gursoy A, Erdogan G, Kamel N. Radioactive iodine treatment in medullary thyroid carcinoma. Nucl Med Commun 2006;27:359-362. (Pubitemid 44315045)
45. Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-310. (Pubitemid 26303135)
46. Stein R, Goldenberg DM. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 2004;3:1559-1564. (Pubitemid 40136711)
47. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.
48. Wells SA, Gosnell JE, Gagel RF, et al. Vendatenib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid carcinoma. J Clin Oncol 2010;28:767-772.